Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530482 | 0.90 | CCR9 (0.81) | CCR9CCR2 | |
| SCHEMBL342214 | 0.79 | CCR9 (0.65) | CCR9CCR2 | |
| SCHEMBL343333 | 0.78 | CCR9 (0.82) | CCR9CCR2 | |
| SCHEMBL343772 | 0.76 | CCR9 (0.69) | CCR9CCR2 | |
| SCHEMBL343310 | 0.74 | CCR9 (0.70) | CCR9CCR2 | |
| SCHEMBL10249554 | 0.74 | CCR9 (1.00) | CCR9CCR2 | |
| SCHEMBL343780 | 0.74 | CCR9 (0.78) | CCR9CCR2 | |
| SCHEMBL5069496 | 0.73 | CCR9 (0.58) | CCR9CCR2 | |
| SCHEMBL20686028 | 0.73 | CCR9 (0.57) | CCR9 | |
| SCHEMBL10284581 | 0.72 | CCR9 (0.62) | CCR9CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8211896-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211896-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-7582661-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582661-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090118307-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118307-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080293717-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293717-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118307-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885 |
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885 |
| US-20080293717-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.